Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

NCT03019185 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03019185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03019185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Lead sponsor
Biogen
Phase
Phase 2/3
Overall status
Completed
Start date
March 2, 2017
Completion date
October 30, 2020
Enrollment
187 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome